Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/33084
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilisation in multiple myeloma
Author: Dyson, P.
Horvath, N.
Joshua, D.
Barrow, L.
Van Holst, N.
Brown, R.
Gibson, J.
To, L.
Citation: Bone Marrow Transplantation, 2000; 25(11):1175-1184
Publisher: Nature Publishing Group
Issue Date: 2000
ISSN: 0268-3369
1476-5365
Statement of
Responsibility: 
P G Dyson, N Horvath, D Joshua, L Barrow, N G Van Holst, R Brown, J Gibson and L B To
Abstract: A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34+ selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PBSC) collection. To evaluate the effectiveness of a protocol combining multiple cycles of high-dose therapy and CD34+ selection to reduce tumour contamination of PBSC autografts, 34 MM patients were entered on a treatment schedule comprising two sequential cycles of mobilisation, CD34+ selection, and transplantation following high-dose therapy. In the second cycle of mobilisation there was a five-fold reduction in tumour contamination of the stem cell harvest (0.5 x 106/kg) compared with the first cycle (2.5 x 106/kg). In the 97 CD34+ selection procedures performed a median of 185 x 108 mononuclear cells (MNC) were processed yielding a median of 0.98 x 108 CD34+-enriched cells. CD34+ cells were enriched 68-fold from 1. 3% to 88.6%. The median yield of CD34+ cells was 42.2%. Following CD34+ selection the tumour cell contamination of the leukapheresis product was reduced by a median of 2.7 logs. This study demonstrates that in multiple myeloma a significant reduction in the malignant contamination of stem cell autografts can be achieved by combining the in vivo purging effect of cytotoxic therapy with in vitro purging by CD34+ selection.
Keywords: Humans; Multiple Myeloma; Cyclophosphamide; Epirubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Recombinant Proteins; Antineoplastic Combined Chemotherapy Protocols; Antigens, CD34; Leukapheresis; Hematopoietic Stem Cell Mobilization; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Transplantation, Autologous; Regression Analysis; Adult; Middle Aged; Female; Male; Biomarkers
Rights: Copyright © 2000 Nature Publishing Group
RMID: 0001002960
DOI: 10.1038/sj.bmt.1702408
Published version: http://www.nature.com/bmt/journal/v25/n11/abs/1702408a.html
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.